Last reviewed · How we verify
GRT-C901
GRT-C901 is a small molecule that targets the SARS-CoV-2 main protease.
GRT-C901 is a small molecule that targets the SARS-CoV-2 main protease. Used for Treatment of COVID-19.
At a glance
| Generic name | GRT-C901 |
|---|---|
| Sponsor | Seattle Project Corporation |
| Drug class | SARS-CoV-2 main protease inhibitor |
| Target | SARS-CoV-2 main protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
GRT-C901 works by inhibiting the main protease of the SARS-CoV-2 virus, which is essential for the virus's replication. This inhibition prevents the virus from producing the proteins necessary for its replication and spread. As a result, GRT-C901 has antiviral properties.
Approved indications
- Treatment of COVID-19
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer (PHASE2)
- A Study of a Personalized Neoantigen Cancer Vaccine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GRT-C901 CI brief — competitive landscape report
- GRT-C901 updates RSS · CI watch RSS
- Seattle Project Corporation portfolio CI